HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.

AbstractOBJECTIVES:
The aim of this study was to compare, in a large all-comer registry, the long-term clinical outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery (ULMCA) stenosis.
BACKGROUND:
Limited data are available regarding clinical outcomes following DES implantation at the different ULMCA sites.
METHODS:
Patients with ULMCA stenosis treated by PCI with DES were analyzed in this multinational registry.
RESULTS:
A total of 1,612 patients were included: 482 were treated for ostial/mid-shaft lesions versus 1,130 for distal bifurcation lesions. At a median follow-up period of 1,250 (interquartile range: 987 to 1,564) days, PCI for distal bifurcation lesions was associated with a higher incidence of major adverse cardiac events (propensity-score adjusted hazard ratio [HR]: 1.48, 95% confidence interval [CI]: 1.16 to 1.89; p = 0.001), largely because of the higher target vessel revascularization rate observed in this group as compared to the ostial/mid-shaft lesions group (propensity-score adjusted HR: 1.68, 95% CI: 1.19 to 2.38; p = 0.003). These results were sustained following propensity-score matched analysis. With regard to all-cause death and the composite endpoint of all-cause death and myocardial infarction, propensity-score adjusted analysis suggested a trend toward higher rates of these in the distal ULMCA PCI group, although this was not observed in the propensity-score matched analysis.
CONCLUSIONS:
This study demonstrates that PCI for ostial/mid-shaft lesions is associated with better clinical outcomes than are distal bifurcation lesions in ULMCA, largely because there is a lower need for repeat revascularization in ostial/mid-shaft lesions.
AuthorsToru Naganuma, Alaide Chieffo, Emanuele Meliga, Davide Capodanno, Seung-Jung Park, Yoshinobu Onuma, Marco Valgimigli, Sanda Jegere, Raj R Makkar, Igor F Palacios, Charis Costopoulos, Young-Hak Kim, Piotr P Buszman, Tarun Chakravarty, Imad Sheiban, Roxana Mehran, Christoph Naber, Ronan Margey, Arvind Agnihotri, Sebastiano Marra, Piera Capranzano, Martin B Leon, Jeffrey W Moses, Jean Fajadet, Thierry Lefevre, Marie-Claude Morice, Andrejs Erglis, Corrado Tamburino, Ottavio Alfieri, Patrick W Serruys, Antonio Colombo
JournalJACC. Cardiovascular interventions (JACC Cardiovasc Interv) Vol. 6 Issue 12 Pg. 1242-9 (Dec 2013) ISSN: 1876-7605 [Electronic] United States
PMID24355114 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Observational Study)
CopyrightCopyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Topics
  • Aged
  • Chi-Square Distribution
  • Coronary Artery Bypass (adverse effects, mortality)
  • Coronary Artery Disease (diagnosis, mortality, surgery, therapy)
  • Coronary Stenosis (diagnosis, mortality, surgery, therapy)
  • Drug-Eluting Stents
  • Europe (epidemiology)
  • Female
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myocardial Infarction (mortality)
  • Percutaneous Coronary Intervention (adverse effects, instrumentation, mortality)
  • Propensity Score
  • Registries
  • Republic of Korea (epidemiology)
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: